- Home
- CPRX
as 02-21-2025 4:00pm EST
Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing, developing therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with Lambert-Eaton myasthenic syndrome.
Upcoming Earnings Alert:
Get ready for potential market movements as Catalyst Pharmaceuticals Inc. CPRX prepares to release earnings report on 26 Feb 2025.
| Founded: | 2002 | Country: | United States |
| Employees: | N/A | City: | CORAL GABLES |
| Market Cap: | 2.8B | IPO Year: | 2006 |
| Target Price: | $32.25 | AVG Volume (30 days): | 875.3K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 1.18 | EPS Growth: | 114.68 |
| 52 Week Low/High: | $13.70 - $24.64 | Next Earning Date: | 02-26-2025 |
| Revenue: | $460,482,000 | Revenue Growth: | 32.17% |
| Revenue Growth (this year): | 24% | Revenue Growth (next year): | 15.13% |
Stock Insider Trading Activity of Catalyst Pharmaceuticals Inc. (CPRX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Miller Steve | CPRX | Chief Op. & Scientific Officer | Dec 9 '24 | Sell | $21.93 | 50,000 | $1,096,350.00 | 686,996 | |
| Harper Molly | CPRX | Director | Nov 27 '24 | Sell | $22.00 | 17,500 | $385,000.00 | 0 | |
| INGENITO GARY | CPRX | Chief Med. & Reg. Officer | Nov 27 '24 | Sell | $22.71 | 12,000 | $272,654.28 | 54,760 | |
| Elsbernd Brian | CPRX | Chief Compliance/Legal Officer | Nov 26 '24 | Sell | $21.61 | 13,256 | $286,703.61 | 165,377 |
Latest Catalyst Pharmaceuticals Inc. News
CPRX Breaking Stock News: Dive into CPRX Ticker-Specific Updates for Smart Investing
Argus Research
3 days ago
CPRX: What does Argus have to say about CPRX?
Investor's Business Daily
3 days ago
Recursion Pharmaceuticals Stock Scores RS Ratings Over 90
Investor's Business Daily
3 days ago
Incyte Stock Sees Relative Strength Rating Rise To 71
Simply Wall St.
5 days ago
Those who invested in Catalyst Pharmaceuticals (NASDAQ:CPRX) five years ago are up 374%
GlobeNewswire
10 days ago
Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2024 Financial Results on February 26, 2025
Argus Research
17 days ago
CPRX: What does Argus have to say about CPRX?
Investor's Business Daily
22 days ago
This Drug Stock Sits On A Strong Earnings Foundation As It Tests New Entry
Investor's Business Daily
22 days ago
Harmony Biosciences Stock Scores 80-Plus RS Rating
Compare CPRX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CPRX Catalyst Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.